• Abstracts must be submitted online through the abstract submission portal by the submission deadline. No faxed, emailed or mailed abstracts will be accepted.
• There is no fee to submit an abstract.
• Authors do not have to be a member of the sponsoring organizations to submit an abstract. 
• Submissions from international attendees and trainees are welcome and encouraged.
• The submitter does not have to be the primary author.

• Abstract submissions will be considered for lecture and poster presentation during Congress sessions taking place Jan. 25 – 27, 2024, at the Bellagio Las Vegas.
• Presenting authors of abstracts accepted for presentation are required to register for and attend the Crohn’s & Colitis Congress to present their abstract at the Bellagio Las Vegas on the date and time specified in their acceptance invitation.
• All abstract presentations will take place in person at the Bellagio Las Vegas. Virtual presentations (e.g., pre-recorded videos or live streams) will not be permitted.

• Abstracts containing basic, clinical, or translational research findings in the field of IBD may be submitted.
• Abstracts that have been previously published as an article or full paper at the Oct. 18 submission deadline will not be considered for presentation.
• Abstracts will not be considered for presentation if they have been or will be presented at a national meeting taking place in the United States before the 2024 Crohn’s & Colitis Congress.
• Abstracts that have been presented at national meetings held outside of the U.S. (e.g., APDW, ECCO, UEG Week, etc.) may be submitted.
• DDW will accept abstract submissions for the 2024 meeting that have been presented at or submitted to other national meetings. Authors may submit an abstract to both the Crohn’s & Colitis Congress and DDW 2024 without penalty.
• Contact info@crohnscolitiscongress.org if you have any questions about abstract eligibility.

When submitting an abstract, authors must select one of the following categories that aligns with their science:

• Adverse Events Related to Therapy
• Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation
• Comparative Effectiveness Studies
• Controlled Clinical Trials in Humans
• COVID and Clinical Practice
• COVID and Interactions with the Microbiome and COVID and Immune Defense
• Cytokines, Signaling and Receptors
• Diagnostics in IBD
• Diarrheal Disorders: Bacterial Overgrowth – Drug Induced and Other Enterocolitis
• Diet and IBD
• Disease Activity Assessment
• Disease Complications
• Epidemiology
• Genomics and Gene Function
• Health Care Delivery and Policy (Practice Management Including Telehealth, COVID-related Issues‚ Reimbursement‚ Access to Care)
• Health Disparities in Patients with GI Disease
• Immune Host Defenses
• Intestinal Inflammation, Fibrosis and Regeneration
• Issues of Provider Diversity, Equity and Inclusion in GI
• Microbiome Role in Intestinal Inflammation
• Mucosal Innate Function and Innate Host Defense: Inflammatory Bowel Disease
• Natural History, Environmental Exposures, and Outcomes
• Non-Immune Cells in Intestinal Inflammation: Epithelium and Stroma
• Omics for Prognosis, Therapeutic Selection, and Mechanisms
• Pediatric IBD: Clinical and Translational Studies
• Phase 2 and 3 Microbial Therapies for IBD
• Practice Management‚ Quality of Care‚ Quality Assurance
• Quality of Life and Psychosocial Care
• Role of Fungi, Viruses and Phages in GI Diseases
• Role of the Gut Microbiome and Pathogens in Immune and Inflammatory Diseases
• Special Populations, Conception, Adolescent, and Older
• Therapeutic Monitoring
• Topics in Global Health (Including Disease Management, Role of Endoscopy, Program Development, Education)
• Translational Application of Intestinal Stem Cells and Organoid Models
• Uncontrolled Therapeutic Observations in Humans Biologic
• Uncontrolled Therapeutic Observations in Humans Non-Biologic
  

   

  Authors can choose ONE topic only for each individual abstract submitted. If an abstract fits into more than one of the submission categories, the submitter should choose the most appropriate one, as abstracts may be submitted only one time to a single category.

• Abstract titles should not exceed 255 characters, including spaces. Please refrain from using commercial names, institution names, non-standard abbreviations or author names in the title.
• All abstract titles must be capitalized. You will not be able to submit an abstract that contains lowercase letters in the abstract title. The use of superscript, subscript and special characters in abstract titles is permitted.
• There is a limit of 2,900 characters, including spaces, for the abstract text. Information included in images submitted as part of the abstract does not count toward this limit.
• Abbreviations may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases.
• Drug products mentioned in abstracts should be identified by their nonproprietary (i.e., generic) names only.
• Abstracts may include up to two images per abstract. Images will only be accepted in gif, png, tiff, tif, jpg, or jpeg formats. PDFs will not be accepted. For assistance taking a screen shot of a Word, Excel or PowerPoint table and saving as an image, follow these instructions on taking a screen shot using Windows or using a Mac. 
• Please format your images appropriately, as images will be published as submitted if accepted for presentation. Be sure to remove any large white borders from images. Large images may be scaled for publication.

Submitted abstracts may be edited any time prior to the submission deadline. To edit an abstract, return it to draft status and then make and save all edits. Edited abstracts must then be resubmitted by the October 18 submission deadline. Abstracts in draft status at the deadline will not be considered for presentation at the meeting.

• The submitter certifies that they have the right to submit the abstract and that the data included in the abstract submission and/or presented at the Crohn’s & Colitis Congress is truthful, original, unduplicated and without fraud or fabrication.
• The submitter certifies all authors listed in the submission are investigators with substantial involvement in the study presented in the abstract.
• By submitting an abstract, the submitting author confirms that he or she has permission from all co-authors to include their names in the submission and that all co-authors are aware of and agree to the content of the abstract and support the data contained therein. Submitting authors may, upon request by Congress administration, be asked to provide proof that all authors have given permission for the submission of the abstract and agree on its content.
• The submitter accepts responsibility for the accuracy of the original data and scientific content of the submitted abstract. Please proofread the abstract carefully prior to submission, as edits to the abstract or author string will not be permitted after the October 18 submission deadline.
• All authors listed on an abstract are required to complete financial disclosure at the abstract submission site by 3 p.m. EDT on Wednesday, October 25, 2023. Abstracts missing financial disclosures will be in jeopardy of not being reviewed and involuntarily withdrawn from consideration for the Congress.
• The submitter confirms that the submitted abstract is an original paper and has not been or will not be presented at a national meeting taking place in the U.S. prior to the 2024 Crohn’s & Colitis Congress.
• The submitter confirms that the submitted abstract has not been previously published as an article or full paper as of the submission deadline.
• The submitter confirms that the abstract has not been submitted to more than one category or submitted by a co-author.
• The submitter confirms that copyright permissions for all third-party material (including and without limitation textual extracts or illustrations, photographs, maps, diagrams and tables) have been obtained.
• By submitting an abstract, the submitter accepts responsibility as the contact person for all correspondence about the abstract and will inform co-authors about its status.
• If an abstract is accepted for presentation at the meeting, the submitting and presenting authors will be sent email communication relevant to presenting abstracts at the meeting, including messages from Congress administration as well as the Congress presentation management and poster vendors.
• Abstracts that include clinical trial data should follow the CONSORT statement.
• Submission of an abstract constitutes a formal commitment by the presenting author to present the abstract in the session and at the time decided upon by the Congress Organizing Committee.
• Presenters are required to register for and attend the 2024 Congress in person. All presentations will take place onsite at the Bellagio Las Vegas. Virtual presentations will not be accommodated.
• Abstracts may be presented only by authors listed in the author string at the time of submission.
• Any change in the presenting author must be communicated in the form of a written statement to the Congress. Failure to present the abstract for other than well-founded reasons could lead to rejection of abstracts submitted to future Crohn’s & Colitis Congress meetings.
• All presentations will be in English. Oral abstract presentations must be made by an author who speaks and understands English.
• Expenses associated with the submission and presentation of an abstract are the sole responsibility of the presenting author.
• If selected for presentation, the copyright of the abstract is released to the Crohn’s & Colitis Foundation and AGA and permission is given for the abstract to be published online supplements in Gastroenterology and Inflammatory Bowel Diseases in January 2024, as well as on the Congress website, mobile application and/or any other official Congress publications.
• If selected for presentation, the copyright of the abstract is released to the Crohn’s & Colitis Foundation and AGA and permission is given for the abstract to be published online supplements in Gastroenterology and Inflammatory Bowel Diseases in January 2024, as well as on the Congress website, mobile application and/or any other official Congress publications.
• Authors whose abstracts are selected for lecture presentation are advised that Congress sessions will recorded and made available to in-person and virtual attendees as on-demand video content.

• All authors are required to complete financial disclosure at the abstract submission site by disclosing financial relationships with ineligible companies over the past 24 months.
• The deadline for completing disclosure is Wednesday, October 25, 2023, at 3 p.m. EDT. 
• Co-authors will receive an automated email message containing a link to the disclosure form after an abstract is successfully submitted.
• When completing the disclosure form, authors will be asked to list the names of the ineligible companies with which they are involved, the benefits received (e.g., salary, consulting fee, ownership interest, etc.) and any roles they play within the named entities (e.g., advisory committee member, board member, employee, shareholder, etc.) over the past 24 months.
• Authors without relationships may state that they have no information to disclose.
• The submitting author is responsible for ensuring that all co-authors submit their financial disclosures by the October 25 deadline. Abstracts missing any co-author financial disclosures may not be reviewed or considered for presentation at the Congress.
• Submitting authors may not submit a disclosure on a co-author’s behalf.

• Congress administration will award up to ten young investigators complementary registration for the 2024 Congress.
• Applicants for the award must be an early career investigator currently in training or within five years of completing their training; additionally, applicants must be listed as the presenting author of an abstract accepted for presentation at the 2024 Crohn’s & Colitis Congress.
• To apply, complete and submit all three award questions as part of the abstract submission by 9 p.m. EDT on Oct. 18, 2023.
• Applicants will be asked to briefly describe their career stage and how Congress attendance will benefit their career in 4000 or fewer characters.
• Applicants are not required to be the submitting author of the abstract; instead, submitting authors may complete the application fields on behalf of the applicant provided that the applicant composes the personal statement.
• Prior award recipients are not eligible to receive a 2024 award.

All data presented at Crohn’s & Colitis Congress is embargoed until 8:30 a.m. PST on the first day of the Congress, Thursday, January 25, 2024.

Abstracts may be made available online to attendees in advance of the Congress for itinerary planning purposes. The embargo policy applies to all abstract data regardless of the date of publication in Congress resources.

The Congress will withdraw abstracts upon written notification from the submitting author by the deadline stated in the notification email. After this date, the Congress cannot guarantee that a withdrawn abstract will be excluded from publication. If circumstances prevent attendance, the presenting author must arrange for the presentation to be given by a co-author. Acceptance of the abstract obligates an author to present the abstract.

1. Read the full abstract submission guidelines.
2. Compose your abstract, ensuring that your abstract adheres to published character count limitations and formatting.
3. Upload up to two images (optional).
4. List all co-authors along with their email addresses and institutions.
5. Review and proof abstract.
6. Finalize abstract and submit online by 9 p.m. EDT on Oct. 18, 2023.
7. Ensure all authors complete their disclosures by 3 p.m. EDT on Oct. 25, 2023.

For abstract related inquiries, please contact info@crohnscolitiscongress.org